

SMi Group Launches new conference: The Transdermal and Microneedle Delivery Conference

SMi Reports: Registration is open for SM's inaugural conference: Transdermal and Microneedle Delivery will take place on 24th - 25th January 2022

LONDON, NON UNITED STATES OR CANADA, UNITED KINGDOM, October 20, 2021 /EINPresswire.com/ -- SMi Group is proud to present the inaugural <u>Transdermal</u> and <u>Microneedle Drug Delivery</u> Conference, taking place on the 24th to 25th



January 2022, in London, UK. The Conference will explore real world applications of microneedles in drug delivery and strategies for device design while engaging in the latest innovations in device design and formulation with case studies from thought leaders.

The conference will also consider key developments in the transdermal drug delivery field, including the innovations in microneedle technology for a COVID-19 vaccine and opportunities for development in cancer vaccine delivery, advances in microarray patches, and microneedle-based diagnostics. Key regulatory updates including guidance on classification of microneedle devices and considerations for ensuring quality will be presented by regulatory experts for a comprehensive outlook of this exciting and ever-growing field, and the importance of considering human factors in order to enhance the user experience will be presented by industry experts.

This two-day agenda offers you peer-to-peer networking with leaders in transdermal and microneedle delivery. A saving of £200 is available for bookings made before 29th October 2020. Visit the website here: www.transdermal-microneedle-delivery.co.uk/PR1EIN

Sponsors of the conference include: LTS Lohmann Therapie-Systeme AG, QuadMedicine

SMi Group offer direct access to key decision makers through tailored sponsorship and exhibitor packages. For details contact Alia Malick, Director on +44 (0)20 7827 6168 or email amalick@smi-

Key Benefits of Attending Include:

- •Gain insight into developments in microneedles for drug delivery and diagnostics
- •Hear key regulatory updates from regulatory bodies including FDA and WHO on guidance for regulatory compliance
- •Explore new applications of microneedle technology in vaccinations
- •Discover advances in design and application of transdermal patches
- •Explore and benchmark against industry developments through case studies and real-world examples in device development for microneedles

Featured Regulatory Speakers:

- Caroline Strasinger, Master Reviewer, Office of Pharmaceuticals Quality, CDER/FDA
- •Bridgitte Giersing, Team Lead, Vaccine Prioritization and Platforms, World Health Organisation

Featured 2022 Speakers Include:

- •Marion Menozzi-Arnaud, Senior Specialist, Market Shaping, Gavi, The Vaccine Alliance
- •Hayley Lewis, Senior Vice President, Zosano Pharma
- Courtney Jarrahian, Program Advisor, PATH
- •Michael Schrader, CEO, Vaxess Technologies, Inc.
- •Clemens Guenther, Director of Senior Expert Nonclinical Safety, Bayer AG
- •James Birchall, Professor of Pharmaceutical Sciences and Deputy Head of School, Cardiff University

Transdermal and Microneedle Delivery
24-25 January 2022
London, UK
www.transdermal-microneedle-delivery.co.uk/PR1EIN
#SMiTransdermal

For media enquiries contact Richard Jones on Tel: +44 (0)20 7827 6088 / Email: rjones@smi-online.co.uk

--- ENDS -

Contact Information:

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Nikisha Galoria

SMi Group 02078276000 email us here

This press release can be viewed online at: https://www.einpresswire.com/article/554324186
EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.